Loading…

Elevated levels of small, low‐density lipoprotein with high affinity for arterial matrix components in patients with rheumatoid arthritis: Possible contribution of phospholipase A2 to this atherogenic profile

Objective This work studied the presence of inflammatory and atherogenic lipoprotein markers that could explain the high incidence of cardiovascular disease (CVD) reported in rheumatoid arthritis (RA) patients. Methods Inflammatory markers were 1) soluble adhesion molecules (intercellular adhesion m...

Full description

Saved in:
Bibliographic Details
Published in:Arthritis and rheumatism 2001-12, Vol.44 (12), p.2761-2767
Main Authors: Hurt‐Camejo, Eva, Paredes, Silvia, Masana, Lluis, Camejo, Germán, Sartipy, Peter, Rosengren, Birgitta, Pedreňo, Javier, Vallve, Joan Carles, Benito, Pere, Wiklund, Olov
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Objective This work studied the presence of inflammatory and atherogenic lipoprotein markers that could explain the high incidence of cardiovascular disease (CVD) reported in rheumatoid arthritis (RA) patients. Methods Inflammatory markers were 1) soluble adhesion molecules (intercellular adhesion molecule [ICAM] and vascular cell adhesion molecule [VCAM]), 2) C‐reactive protein (CRP), 3) fibrinogen (Fb), 4) cytokines (interferon‐γ [IFNγ], tumor necrosis factor α [TNFα]), and 5) secretory group IIA phospholipase A2(sPLA2‐IIA). Atherogenic lipoprotein markers were 1) the size distribution of plasma lipoprotein subclasses, and 2) the binding affinity of low‐density lipoprotein (LDL) to chondroitin 6‐sulfate glycosaminoglycan (GAG). Results RA patients (n = 31) and matched controls (n = 28) had similar plasma concentrations of total cholesterol, triglycerides, Apo B, Apo A‐I, very low‐density lipoprotein, intermediate‐density lipoprotein, and high‐density lipoprotein (HDL). RA patients had significantly higher plasma levels of sPLA2‐IIA, ICAM, CRP, Fb, TNFα, and IFNγ compared with controls. RA patients also had significantly higher levels of small, dense LDL‐1 (P < 0.05) and lower levels of small HDL‐2 particles (P < 0.001) compared with controls. In addition, LDL from RA patients had a significantly higher binding affinity (Kd) to GAG (mean ± SD Kd 204 ± 22.4 nM Apo B) than did LDL from control subjects (Kd 312 ± 36 nM Apo B) (P < 0.05). This Kd value showed a significant negative correlation with the plasma levels of LDL‐1 (r = −0.566, P ≤ 0.004). In RA patients, a significant positive correlation was obtained between sPLA2‐IIA and CRP, ICAM, and LDL‐1. HDL‐2 showed a negative correlation with sPLA2‐IIA. Conclusion These atherogenic lipoprotein factors combined with the presence of chronic inflammation may contribute to the high CVD‐related mortality in RA patients.
ISSN:0004-3591
1529-0131
DOI:10.1002/1529-0131(200112)44:12<2761::AID-ART463>3.0.CO;2-5